BACKGROUND: Isosulfan Blue dye (BD) allergic drug reactions (ADR) occur in up to 2% of patients undergoing SLN biopsy (SLNB). We sought to determine if BD enhances the performance of SLNB such that this risk is justified. METHODS: A retrospective review of 392 breast cancer patients undergoing SLNB between 8/99 and 8/04 was performed; 208 patients had radioisotope (ISO) alone, 167 had ISO+BD. Total SLN and positive SLN in each group were compared. We examined the ISO+BD group for concordance and the presence of blue only nodes. The effect of tumor location, injection site, angiolymphatic invasion, Her2/neu expression, and the presence of a noninvasive component were studied. Chi-square, linear regression, Fisher t tests, and ANOVA were performed. RESULTS: SLN were identified in 94% of ISO and 96% of ISO+BD patients. The mean number SLN from the ISO group was 2.01, 1.93 for ISO+BD; 27% of ISO and 21% of ISO+BD patients had positive nodes. These differences were not significant. No difference for tumor location, injection site, angiolymphatic invasion, Her2/neu expression, or the presence of a noninvasive component was found. CONCLUSION: The addition of BD to ISO in patients with invasive breast cancer does not significantly enhance the performance of SLNB.
BACKGROUND:Isosulfan Blue dye (BD) allergic drug reactions (ADR) occur in up to 2% of patients undergoing SLN biopsy (SLNB). We sought to determine if BD enhances the performance of SLNB such that this risk is justified. METHODS: A retrospective review of 392 breast cancerpatients undergoing SLNB between 8/99 and 8/04 was performed; 208 patients had radioisotope (ISO) alone, 167 had ISO+BD. Total SLN and positive SLN in each group were compared. We examined the ISO+BD group for concordance and the presence of blue only nodes. The effect of tumor location, injection site, angiolymphatic invasion, Her2/neu expression, and the presence of a noninvasive component were studied. Chi-square, linear regression, Fisher t tests, and ANOVA were performed. RESULTS:SLN were identified in 94% of ISO and 96% of ISO+BD patients. The mean number SLN from the ISO group was 2.01, 1.93 for ISO+BD; 27% of ISO and 21% of ISO+BD patients had positive nodes. These differences were not significant. No difference for tumor location, injection site, angiolymphatic invasion, Her2/neu expression, or the presence of a noninvasive component was found. CONCLUSION: The addition of BD to ISO in patients with invasive breast cancer does not significantly enhance the performance of SLNB.
Authors: Martin Sillem; Urban Bromberger; Barbara Heitzelmann; Wolfgang J Brauer; Martin Werner; Sylvia Timme Journal: Breast Care (Basel) Date: 2015-12-21 Impact factor: 2.860